# First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

> **NCT05920135** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bridge Biotherapeutics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- EGFR Mutant Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** BBT-207

## Key facts

- **NCT ID:** NCT05920135
- **Lead sponsor:** Bridge Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-11
- **Primary completion:** 2026-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920135, "First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05920135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*